Inhaled Antibiotics for Non-Cystic Fibrosis Bronchiectasis
Current Approval Status and Evidence
- The FDA has not approved inhaled tobramycin or colistin for use in non-cystic fibrosis bronchiectasis, despite their clinical use in this population 1
- Inhaled tobramycin is FDA-approved for cystic fibrosis bronchiectasis in patients 6 years and older with Pseudomonas aeruginosa infection, but not for non-CF bronchiectasis 1
- The European Respiratory Society guidelines state there is insufficient evidence to recommend routine use of nebulized tobramycin in non-CF bronchiectasis 1, 2
- Inhaled colistin lacks FDA approval for non-CF bronchiectasis treatment 2
Clinical Evidence for Non-CF Bronchiectasis
- The British Thoracic Society (BTS) guidelines recommend inhaled colistin for patients with bronchiectasis and chronic Pseudomonas aeruginosa infection (Grade B recommendation) 3
- Comparative studies show colistin is less effective than tobramycin, with one study showing no improvement in lung function with colistin while tobramycin increased FEV1 by 6.7% 4, 5
Safety Considerations
- Bronchospasm is a significant concern, reported in multiple studies, with wheezing observed in 50% of patients treated with inhaled tobramycin in one study 2
- Patients with kidney disease or ear disorders should be treated with caution due to potential systemic absorption 1
Treatment Approach Based on Current Evidence
- The BTS guidelines suggest using inhaled colistin as first-line therapy for patients with non-CF bronchiectasis and chronic P. aeruginosa infection who have frequent exacerbations 3
- Inhaled gentamicin can be considered as a second-line alternative for patients with non-CF bronchiectasis and chronic P. aeruginosa infection 3
- Macrolides (azithromycin or erythromycin) may be used as alternatives if patients cannot tolerate inhaled antibiotics 3